AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27765906 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment received
Number of subjects: 34
Study 27765906 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful xenografting
Number of subjects: 34
Study 27765906 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic-driven treatment implementation
Number of subjects: 34
Study 27766064 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiwanese PNH patients
Number of subjects: 63
Study 27766119 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial medication (levothyroxine) for 24 weeks
Number of subjects: 48
Study 27766119 — intervention group
Group type: COMPARATOR
Intervention: Usual TSH arm
Number of subjects: 48
Study 27766119 — intervention group
Group type: COMPARATOR
Intervention: Higher TSH arm
Number of subjects: 48
Study 27766119 — intervention group
Group type: COMPARATOR
Intervention: Home visits
Number of subjects: 48
Study 27766119 — intervention group
Group type: COMPARATOR
Intervention: Research Facility visits
Number of subjects: 48
Study 27766602 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-Eden-VIR/Novirin (1-4 capsules per day for 2-48 months)
Number of subjects: 137
Study 27766602 — intervention group
Group type: COMPARATOR
Intervention: Baseline control group
Number of subjects: 137
Study 27766602 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 137
Study 27766602 — intervention group
Group type: COMPARATOR
Intervention: Dose-response control group
Number of subjects: 137
Study 27767222 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy (mechanical debridement plus 1 week of amoxicillin/metronidazole)
Number of subjects: 141
Study 27767943 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-assisted occupational therapy intervention
Number of subjects: 7
Study 27767943 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (control group not explicitly mentioned)
Number of subjects: 7
Study 27768852 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood socioeconomic variables (poverty rate, percentage of single-female-headed households)
Number of subjects: 774
Study 27768852 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 774
Study 27768852 — intervention group
Group type: COMPARATOR
Intervention: Controlling for poverty rate or percentage of single-female-headed households
Number of subjects: 774
Study 27768855 — intervention group
Group type: EXPERIMENTAL
Intervention: Coastal region
Number of subjects: 299
Study 27768855 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban region
Number of subjects: 299
Study 27768855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mountainous region
Number of subjects: 299
Study 27768855 — intervention group
Group type: COMPARATOR
Intervention: Overall assessment
Number of subjects: 299
Study 27768923 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet hepatic artery infusion (HAI) and intravenous cetuximab (500 mg/m² cetuximab, 180 mg/m² irinotecan)
Number of subjects: 64
Study 27768923 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet hepatic artery infusion (HAI) and intravenous cetuximab
Number of subjects: 64
Study 27769214 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker panel combined with mp-MRI and VERDICT MRI
Number of subjects: 365
Study 27769214 — intervention group
Group type: COMPARATOR
Intervention: mp-MRI
Number of subjects: 365
Study 27769214 — intervention group
Group type: EXPERIMENTAL
Intervention: VERDICT MRI
Number of subjects: 365
Study 27770592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight adiponectin increase in Type 2 diabetes
Number of subjects: 136
Study 27770592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight/total adiponectin ratio increase in Type 2 diabetes
Number of subjects: 136
Study 27770592 — intervention group
Group type: EXPERIMENTAL
Intervention: Total adiponectin increase in Type 1 diabetes
Number of subjects: 136
Study 27770695 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 176
Study 27770774 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery including pseudarthrosis resection, intramedullary rodding, autogenous iliac bone grafting and Ilizarov's fixator.
Number of subjects: 56
Study 27771496 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-90 ibritumomab-tiuxetan as part of reduced-intensity conditioning (RIC)
Number of subjects: 0
Study 27771496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 250 mg (days -21 and -14)
Number of subjects: 0
Study 27771496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m2
Number of subjects: 0
Study 27771496 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27771544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400mg twice daily for 24 months
Number of subjects: 45
Study 27771610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib (1.5 mg daily, 3 weeks on 1 week off, 28-day cycle)
Number of subjects: 58
Study 27773811 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical resection of adhesions (TCRA) and endometrial biopsy
Number of subjects: 82
Study 27774033 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin solution challenge
Number of subjects: 4
Study 27774033 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 4
Study 27774059 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Upper Limb Therapy-Integrated (MULT-I), 45-min intervention, twice a week for 6 weeks
Number of subjects: 13
Study 27774495 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatments
Number of subjects: 1038
Study 27774495 — intervention group
Group type: COMPARATOR
Intervention: Cervical dystonia
Number of subjects: 1038
Study 27774730 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center daily hemodialysis (6 days/week)
Number of subjects: 237
Study 27774730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis (6 nights/week)
Number of subjects: 237
Study 27774730 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice weekly hemodialysis
Number of subjects: 237
Study 27774758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (Absorb BVS) implantation
Number of subjects: 500
Study 27775823 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM-CBT (Cognitive Behavioral Therapy)
Number of subjects: 227
Study 27775823 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM-CBT
Number of subjects: 227
Study 27775823 — intervention group
Group type: COMPARATOR
Intervention: CBT plus medication management
Number of subjects: 227
Study 27775823 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CBT dose
Number of subjects: 227
Study 27775823 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 227
Study 27776521 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) administered under direct observation with a fat intake consisting of ready-to-use therapeutic food (RUTF - Plumpy'Nut®), twice daily during 3 days.
Number of subjects: 399
Study 27776526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 2351
Study 27776526 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure component of MetS
Number of subjects: 2351
Study 27776526 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL)
Number of subjects: 2351
Study 27776526 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 2351
Study 27777218 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia version of Taipei II developmental screening tool
Number of subjects: 390
Study 27777218 — intervention group
Group type: COMPARATOR
Intervention: Paper-based version of Taipei II developmental screening tool
Number of subjects: 390
Study 27777269 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention with placebo control
Number of subjects: 0
Study 27777269 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study 27777278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital EMS-initiated CPR
Number of subjects: 12877
Study 27777278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander-initiated CPR
Number of subjects: 12877
Study 27777294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring annuloplasty with consideration of left ventricular (LV) size
Number of subjects: 214
Study 27777294 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger LV end-systolic dimension (LVESd)
Number of subjects: 214
Study 27777294 — intervention group
Group type: EXPERIMENTAL
Intervention: LVESd/ring size ratio
Number of subjects: 214
Study 27777594 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen exposure
Number of subjects: 38
Study 27777606 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Rite Cola™ (18 mg sucralose, 18 mg acesulfame-potassium, 57 mg aspartame)
Number of subjects: 61
Study 27777606 — intervention group
Group type: COMPARATOR
Intervention: NNS in water (0 mg, 68 mg, 170 mg, 250 mg sucralose)
Number of subjects: 61
Study 27777606 — intervention group
Group type: COMPARATOR
Intervention: NNS in water
Number of subjects: 61
Study 27777612 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment of panic disorder
Number of subjects: 0
Study 27777612 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 27777873 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% mannitol
Number of subjects: 52
Study 27777873 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 52
Study 27778193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) 9 g/night
Number of subjects: 228
Study 27778193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (SXB) (all doses)
Number of subjects: 228
Study 27778193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 27778639 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa (300 mg, 3 times a day)
Number of subjects: 1
Study 27778639 — intervention group
Group type: COMPARATOR
Intervention: Treatment-naive conditions
Number of subjects: 1
Study 27779248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous busulfan (Bu)
Number of subjects: 76
Study 27779436 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 543
Study 27779572 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol
Number of subjects: 51
Study 27780238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulitis cases with lower extremity blisters
Number of subjects: 201
Study 27780238 — intervention group
Group type: EXPERIMENTAL
Intervention: Abscess cases with methicillin-resistant S. aureus (MRSA) colonization
Number of subjects: 201
Study 27780238 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome analysis of cellulitis aspirates
Number of subjects: 201
Study 27780238 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome evaluation of aspirate specimens
Number of subjects: 201
Study 27780238 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome evaluation of abscess specimens
Number of subjects: 201
Study 27780778 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state functional connectivity using 7T fMRI
Number of subjects: 32
Study 27780903 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion (defined as modified Treatment in Cerebral Ischemia grade of 2b to 3)
Number of subjects: 83
Study 27780903 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombi retrieved from the reperfused group
Number of subjects: 83
Study 27780903 — intervention group
Group type: COMPARATOR
Intervention: Atheromatous gruel
Number of subjects: 83
Study 27780903 — intervention group
Group type: COMPARATOR
Intervention: >64% erythrocyte components
Number of subjects: 83
Study 27781135 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1-3 mg/day
Number of subjects: 37
Study 27781241 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectum excision (TME) with guidance of membrane anatomy
Number of subjects: 0
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Early satiety (ES) severity
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial fullness (PPF) severity
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with other symptoms
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with gastroparesis severity
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with BMI
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with quality of life
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with gastric retention
Number of subjects: 198
Study 27781342 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ES and PPF with water load test
Number of subjects: 198
Study 27782373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/simeprevir plus flat dose ribavirin (800 mg/d) for 12 weeks
Number of subjects: 270
Study 27782769 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports on the Screener and Opioid Assessment for Patients with Pain®-Revised questionnaire
Number of subjects: 2171
Study 27782769 — intervention group
Group type: COMPARATOR
Intervention: Investigator assessment
Number of subjects: 2171
Study 27782769 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports on the Self-Reported Misuse, Abuse, and Diversion questionnaire
Number of subjects: 2171
Study 27782769 — intervention group
Group type: EXPERIMENTAL
Intervention: Current Opioid Misuse Measure
Number of subjects: 2171
Study 27782769 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine drug tests (UDTs)
Number of subjects: 2171
Study 27782854 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-matched trials
Number of subjects: 1640
Study 27782854 — intervention group
Group type: COMPARATOR
Intervention: Genotype-unmatched trials
Number of subjects: 1640
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with pneumonia etiology
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with non-infectious diagnoses
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with opportunistic infection
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory failure with undetermined etiology
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospital mortality in patients with ARF
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive pulmonary aspergillosis
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of invasive mechanical ventilation
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score >7
Number of subjects: 604
Study 27783381 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetermined ARF etiology
Number of subjects: 604
Study 27783539 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPTURE with PEF
Number of subjects: 346
Study 27783539 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified intervention)
Number of subjects: 346
Study 27784272 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline examinations including biochemistry, 24-h Holter ECG recordings, 24-h ambulatory blood pressure measurement, 24-h pulse wave analysis and pulse wave velocity, retinal vessel analysis, and neurocognitive testing.
Number of subjects: 500
Study 27784272 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examinations after 24 months including biochemistry, single PWA, single PWV, and neurocognitive testing.
Number of subjects: 500
Study 27784272 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for up to 6 years for hospitalizations, cardiovascular events, non-cardiovascular events, cardiovascular mortality, and all-cause mortality.
Number of subjects: 500
Study 27784331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 0
Study 27784746 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLX101
Number of subjects: 0
Study 27784746 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLX101 and 5-fluorouracil
Number of subjects: 0
Study 27784751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole
Number of subjects: 61
Study 27784821 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe chronic hyperglycemia (>42 mmol/mol)
Number of subjects: 812
Study 27784821 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe chronic hyperglycemia (>42 mmol/mol) after adjustment for confounding factors
Number of subjects: 812
Study 27784821 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate chronic hyperglycemia (39-42 mmol/mol)
Number of subjects: 812
Study 27785036 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS) with sensor-embedded tablets of aripiprazole, 8-week treatment.
Number of subjects: 67
Study 27786499 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental message
Number of subjects: 722
Study 27786499 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering message
Number of subjects: 722
Study 27786499 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mediator measures
Number of subjects: 722
Study 27786499 — intervention group
Group type: EXPERIMENTAL
Intervention: No mediator measures
Number of subjects: 722
Study 27787664 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-free treatment
Number of subjects: 3474
Study 27787778 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 mg and 25 mg doses)
Number of subjects: 2639
Study 27787778 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (SU)
Number of subjects: 2639
Study 27788018 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of Events Scale-Revised
Number of subjects: 0
Study 27788018 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Traumatic Stress Symptoms instrument
Number of subjects: 0
Study 27788131 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-induced DNA damage
Number of subjects: 2
Study 27788131 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous DNA damage
Number of subjects: 2
Study 27788856 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Number of subjects: 0
Study 27788856 — intervention group
Group type: COMPARATOR
Intervention: Sham Procedure
Number of subjects: 0
Study 27788880 — intervention group
Group type: EXPERIMENTAL
Intervention: pnfC1-INH (20 IU/kg per HAE attack)
Number of subjects: 46
Study 27789021 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered autologous nasal chondrocyte-based cartilage grafts
Number of subjects: 10
Study 27789145 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV3 in children
Number of subjects: 44
Study 27789145 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3 in adults
Number of subjects: 44
Study 27789145 — intervention group
Group type: COMPARATOR
Intervention: LAIV3 in adults
Number of subjects: 44
Study 27789145 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3 and LAIV3 in children and adults
Number of subjects: 44
Study 27789147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfs25H-EPA/Alhydrogel® vaccine candidate
Number of subjects: 0
Study 27789147 — intervention group
Group type: COMPARATOR
Intervention: Direct skin feeding assay (DSF)
Number of subjects: 0
Study 27789517 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate receptor inhibitors (ADPri) therapy
Number of subjects: 11858
Study 27789517 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 11858
Study 27789517 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 11858
Study 27789517 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 11858
Study 27789517 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11858
Study 27789517 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cessation of ADPri therapy
Number of subjects: 11858
Study 27789541 — intervention group
Group type: EXPERIMENTAL
Intervention: PwMS
Number of subjects: 105
Study 27789541 — intervention group
Group type: EXPERIMENTAL
Intervention: PwCIS
Number of subjects: 105
Study 27789541 — intervention group
Group type: COMPARATOR
Intervention: HS
Number of subjects: 105
Study 27789678 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB039110 (selective JAK1 inhibitor)
Number of subjects: 0
Study 27790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight fraction of 5% human serum albumin (LMWF-5A)
Number of subjects: 329
Study 27790041 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 329
Study 27790201 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection
Number of subjects: 0
Study 27790201 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27790729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus simeprevir ± ribavirin
Number of subjects: 240
Study 27790729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 240
Study 27790763 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR dose of allergen extract daily, by sublingual route
Number of subjects: 0
Study 27790763 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 27791054 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 27791054 — intervention group
Group type: EXPERIMENTAL
Intervention: High ELS
Number of subjects: 0
Study 27791054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ELS
Number of subjects: 0